ACEPHAP Trains Research Staff on Simplified Eclampsia Prevention Regimen
The African Centre of Excellence for Population Health and Policy (ACEPHAP) conducted a three-day training for data collection research staff from 28th to 30th January 2026, focused on the use of a simplified magnesium sulfate regimen for the prevention of eclampsia.
The training forms part of a Phase 3 clinical trial designed as a randomized, open-label, active-controlled, multi-country, multi-centre non-inferiority study. The primary objective of the trial is to evaluate whether a simplified magnesium sulfate regimen—10 g administered intramuscularly every 12 hours for two doses—is as effective as standard regimens in preventing maternal eclamptic seizures.
The standard regimens under comparison include the Zuspan regimen, which involves a 4 g intravenous loading dose followed by a continuous infusion of 1 g per hour for 24 hours, and the Pritchard regimen, which consists of a 4 g intravenous and 10 g intramuscular loading dose followed by 5 g intramuscular injections every four hours for 24 hours.
Participants were trained on key components of trial implementation, including participant eligibility assessment, informed consent procedures, randomization processes, treatment administration, and accurate data documentation. Practical role-play sessions were used to strengthen understanding of informed consent and ensure adherence to ethical standards.
A major highlight of the training was a Good Clinical Practice (GCP) session led by the Director of ACEPHAP, Prof. Hadiza Galadanci. She emphasized ethical conduct, participant safety, and data integrity as essential requirements for high-quality clinical research and reaffirmed the Centre’s commitment to globally aligned research standards.
The study aims to generate evidence that could support the use of simplified treatment protocols for eclampsia prevention, particularly in low-resource settings where access to complex treatment regimens may be limited.
You can join the conversation on:
- Instagram: @acephap_buk
- LinkedIn: @acephap
- Facebook: @acephap
- X/Twitter: @acephap_buk
